International

Lung Cancer Summit

7th October 2022

Lausanne University Hospital

View ProgramRegister Now

Our Chairs Invite You To Join!

Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 4th edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase the latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide exceptional outreach and opportunities for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, Ireland, Israel, South Africa, Austria and Switzerland.

Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

5 SGMO CME Credits

CME-Accredited

This meeting is accredited and CME-certified! Add this event to your calendar by selecting your calendar and download your certificate of attendance during the conference.

Swiss Society of Medical Oncology: 5 credit points

European Accreditation Council for Continuing Medical Education (EACCME): 4 credit points

Our Faculty

Jordi Remón

Gustave Roussy,
Villejuif, France

Jarushka Naidoo

Beaumont Hospital
Dublin, Ireland

Sandip Patel

UC Moores Cancer Center,
San Diego, USA

Alessandra Curioni

Cantonal Hospital
Fribourg, Switzerland

Stephen V. Liu

Georgetown Lombardi Ca. Center,
DC, USA

Noemi Reguart

Hospital Clinic
Barcelona, Spain

Wolf Janthur

Cantonal Hospital
Aarau, Switzerland

Sabina Berezowska

University Hospital
Lausanne, Switzerland

Sze Wai Chan

Sandton Oncology Centre
Johannesburg, South Africa

Jair Bar

Chaim Sheba Medical Center
Tel Aviv, Israel

Send us your questions for discussion

Our Program

Friday, 7 October 2022 – Live In Lausanne

Indicated Time Zone: Central European Summer Time (CEST)

10.00

Welcome by Chairs

Solange Peters & Alfredo Addeo

10.02

The power of pathology: biomarkers and targets we are testing today

Sabina Berezowska (Switzerland)

10.20

The many faces of EGFR mutations: each a different target

Alessandra Curioni (Switzerland)

10.45

ALK: old known with new expanded therapeutic options

Sze-Wai Chan (South Africa)

11.15

Open discussion & coffee break

11.30

Drugging the undruggables: the advent of KRAS and HER2 in NSCLC

Jair Bar (Israel)

11.50

METex14 and RET: important oncogenic factors for our treatment decision

Jordi Remón (France)

12.30

MSD Satellite Symposium

“Surgery and immunooncology – advancing the outcomes in the peri-operative setting of early-stage NSCLC”
Alessandra Curioni & Walter Weder (Switzerland)

13.00

Sanofi Satellite Symposium

“Advanced NSCLC: Relevance of subgroup analysis and PROs”
Carolin Lips & Alfredo Addeo (Switzerland)

14.00

Immunotherapies in good companionship: where do combination therapies make sense in advanced NSCLC – and where not?

Jarushka Naidoo (Ireland)

14.30

DEBATE:

OS vs. DFS in early NSCLC

Disease free survival is an adequate endpoint for immuno- and targeted therapies in adjuvant NSCLC

Noemi Reguart (Spain)

14.45

DEBATE:

OS vs. DFS in early NSCLC

OS is the only meaningful endpoint – also for adjuvant therapies

Wolf-Dieter Janthur (Switzerland)

15.00

Open discussion & coffee break

15.20

The path of immunotherapies to early NSCLC: my choice in stage I -III

Sandip Patel (USA)

15.50

Small Cell Lung Cancer: what are our options for SCLC in 1st and 2nd line today?

Stephen V. Liu (USA)

16.20

Do we follow our own commitments that we take away from congresses?

Panel Discussion With All

Join Us In Lausanne

Centre hospitalier universitaire vaudois - CHUV
Fondation ISREC, Bâtiment AGORA
Rue du Bugnon 25A
1005 Lausanne, Switzerland

Our Sponsors

The Intl. Lung Cancer Summit 2022 is supported by our partners, with no influence on the content:

MSD Logo
Janssen Logo
AstraZeneca Logo
Amgen Logo
Sanofi
Roche Logo
Takeda Logo
Novartis Logo
Eli Lilly Logo
PharmaMar
Merck Logo
Pfizer Logo
BMS Logo
Daiichi Sankyo
Frontiers Logo

for sponsoring opportunities, please contact us at sponsoring@lungcancersummit.org

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Follow Us For The Latest News on Twitter & LinkedIn

"The #LungSummit is a must & a place where you can be updated on the latest advances that are happening in #ThoracicOncology", says @NReguart who will be joining us at @OncoUNILCHUV to debate on DFS as an endpoint for trials in eNSCLC

Join us next week http://lungcancersummit.org 🎥

Image for the Tweet beginning: "The #LungSummit is a must

Be sure to join Dr. @StephenVLiu from @Georgetown & @LombardiCancer for this year's #LungSummit at @CHUVLausanne.
We look very much forward to discussing the latest therapeutic options in #SCLC and beyond!

Register for free today at http://lungcancersummit.org & join us next week 🗓️

Image for the Tweet beginning: Be sure to join Dr.

OS as the only meaningful endpoint for clinical benefit – also for adjuvant therapies? Join the debate🤔
Connect with Wolf-Dieter Janthur from @ksagruppe & discuss your opinions at the upcoming #LungSummit!

Tune in next week for this & much more.Register: http://lungcancersummit.org

Image for the Tweet beginning: OS as the only meaningful

Is disease-free survival an adequate endpoint for immuno- & targeted therapies in adjuvant NSCLC? 🤔

Join and connect with @NReguart from @hospitalclinic on this exciting debate next week at the annual #LungSummit 🫁

Tune in live or virtually online ➡️ http://lungcancersummit.org

Image for the Tweet beginning: Is disease-free survival an adequate

#Immunotherapy for #LungCancer is continually evolving 💊

Join @DrJNaidoo from @CancerCentreIre on her talk on combination therapies in advanced #NSCLC - where do they make sense? 🤔

Tune in next week for free ➡️ http://lungcancersummit.org

Image for the Tweet beginning: #Immunotherapy for #LungCancer is continually

Discovering new targets for the treatment of #LungCancer can be a challenge 🤔

Join @JairBar4 from @sheba_medical at the upcoming #LungSummit to discuss available treatment options & challenges for #HER2 & #KRAS mutated #NSCLC 💊

Register now for free ➡️ http://lungcancersummit.org

Image for the Tweet beginning: Discovering new targets for the

We're excited to have Sze-Wai Chan from Sandton Oncology Centre, South Africa, at this year's #LungSummit 🫁

Discover her talk on #ALK and therapeutic options in #LungCancer at the upcoming event, live or virtually online 🎥

Register now for free ➡️ http://lungcancersummit.org

Image for the Tweet beginning: We're excited to have Sze-Wai
Load More...